Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-003 + Sunitinib in Advanced RCC
NCT00678119Phase 2Completed
- Sponsor
- Argos Therapeutics
- Start
- Jan 2008
- Primary completion
- May 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rocapuldencel-T in renal cell carcinoma (RCC), sponsored by Argos Therapeutics. Primary endpoint: Objective Tumor Response at 24 weeks. Started Jan 2008; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00678119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678119.